Folic Acid Buffered Diluent (Liquid Stable)

Folic Acid Buffered Diluent (Liquid Stable)

Folic Acid Buffered Diluent (Liquid Stable) is a biotechnology-grade reagent formulated to support the preparation of folic acid working solutions for assay calibration and reagent development. This depleted folate matrix is specifically designed for use with the High Folic Acid Buffered Solution (Catalog B2010580), enabling researchers to generate precise high and low folate concentrations for immunoassay validation, quality control, and standard curve construction. Its liquid-stable format ensures ease of use and consistent performance across manual and automated workflows.

Researchers in clinical diagnostics, nutritional biochemistry, and metabolic health rely on folate diluents to simulate physiological conditions and optimize assay sensitivity. This buffer provides a clean, folate-depleted background that supports accurate quantification of folic acid in serum, plasma, and fortified food samples. Filtered through 0.22 m membranes and prepared with ultrapure water, it minimizes background interference and ensures high reproducibility. Supplied in a 50 mL format and stored at 28C, it integrates seamlessly into ELISA, CLIA, and other folate detection platforms.

Key benefits:

• Liquid-stable diluent for folic acid assay calibration and reagent formulation

• Designed for use with High Folic Acid Buffered Solution (Catalog B2010580)

• Provides a folate-depleted matrix for accurate quantification

• Filtered through 0.22 m membranes using ultrapure water

• Supplied in 50 mL format and stored at 28C for long-term stability

Products are for in vitro research use only (RUO).

References

• 1: Tian H, Tian D, Zhang C, Wang W, Wang L, Ge M, Hou Q, Zhang W. Efficacy of
  Folic Acid Therapy in Patients with Hyperhomocysteinemia. J Am Coll Nutr. 2017
  Sep-Oct;36(7):528-532.

• 2: Saussele T. Folsuresupplementierung vor und whrend der Schwangerschaft
  [Supplementation with folic acid before and during pregnancy]. Med Monatsschr
  Pharm. 2008 Dec;31(12):469-72.

• 3: Goto S, Fujii H, Kim JI, Fukagawa M. Homocysteine and folic acid levels in
  hemodialysis patients treated with sevelamer hydrochloride. Clin Nephrol. 2010
  Jun;73(6):420-5.

• 4: Strhle A, Wolters M, Hahn A. Folic acid and colorectal cancer prevention:
  molecular mechanisms and epidemiological evidence (Review). Int J Oncol. 2005
  Jun;26(6):1449-64.

• 5: Yang NV, Pannia E, Chatterjee D, Kubant R, Ho M, Hammoud R, Pausova Z,
  Anderson GH. Gestational folic acid content alters the development and function
  of hypothalamic food intake regulating neurons in Wistar rat offspring post-
  weaning. Nutr Neurosci. 2020 Feb;23(2):149-160.

• 6: Petersen LF, Brockton NT, Bakkar A, Liu S, Wen J, Weljie AM, Bismar TA.
  Elevated physiological levels of folic acid can increase in vitro growth and
  invasiveness of prostate cancer cells. BJU Int. 2012 Mar;109(5):788-95.

• 7: Lucock M, Yates Z. Folic acid fortification: a double-edged sword. Curr Opin
  Clin Nutr Metab Care. 2009 Nov;12(6):555-64.

• 8: Paul RT, McDonnell AP, Kelly CB. Folic acid: neurochemistry, metabolism and
  relationship to depression. Hum Psychopharmacol. 2004 Oct;19(7):477-88.

• 9: Chakraborty H, Nyarko KA, Goco N, Moore J, Moretti-Ferreira D, Murray JC,
  Wehby GL. Folic Acid Fortification and Womens Folate Levels in Selected
  Communities in Brazil A First Look. Int J Vitam Nutr Res. 2014;84(5-6):286-94.

• 10: Gisondi P, Fantuzzi F, Malerba M, Girolomoni G. Folic acid in general
  medicine and dermatology. J Dermatolog Treat. 2007;18(3):138-46.